Cisplatin Tumor Biodistribution and Efficacy after Intratumoral Injection of a Biodegradable Extended Release Implant
Author(s) -
Ariella Shikanov,
Sergey Shikanov,
Boris Vaisman,
Jacob Golenser,
Abraham J. Domb
Publication year - 2011
Publication title -
chemotherapy research and practice
Language(s) - English
Resource type - Journals
eISSN - 2090-2115
pISSN - 2090-2107
DOI - 10.1155/2011/175054
Subject(s) - cisplatin , medicine , biodistribution , implant , pharmacology , drug delivery , toxicity , chemotherapy , pharmacokinetics , drug , in vivo , surgery , chemistry , microbiology and biotechnology , organic chemistry , biology
Local delivery of chemotherapeutic drugs has long been recognized as a potential method for reaching high drug doses at the target site while minimizing systemic exposure. Cisplatin is one of the most effective chemotherapeutic agents for the treatment of various tumors; however, its systemic toxicity remains the primary dose-limiting factor. Here we report that incorporation of cisplatin into a fatty acid-based polymer carrier followed by a local injection into the solid tumor resulted in a successful tumor growth inhibition in heterotopic mouse bladder tumor model in mice. Platinum concentration in the tumor tissue surrounding the injected implant remained above the therapeutic level up to 14 days after the injection, while the plasma levels were several orders of magnitude lower comparing to systemic delivery. The reported delivery system increased the maximum tolerated dose of cisplatin 5 times compared to systemic delivery, thus potentially improving antitumor efficacy of cisplatin in solid tumor model.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom